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ABSTRACT
The distribution of IgG antibodies to Bordetella
pertussis was investigated in serum samples from
550 subjects, aged 4–24 years, to determine the
optimal age for booster immunisation. Levels of
antibody to B. pertussis antigens were determined
using an ELISA that measures a mixture of
pertussis toxin, ﬁlamentous haemagglutinin and
lipopolysaccharide. Geometric mean titres of anti-
pertussis antibodies in subjects aged 4–6 years
were signiﬁcantly lower than those in other age
groups, which reﬂects waning immunity follow-
ing vaccination. High positive titres in older
children and adolescents suggested acquired
B. pertussis infection, and booster doses at the
ages of 7 and 15 years are therefore suggested.
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Even if the cellular and humoral immune
responses are both involved in conferring protec-
tion against Bordetella pertussis [1], determination
of the seroepidemiology of pertussis makes
possible the evaluation of patterns of pertussis
immunity in a given population, and helps deﬁne
the target population for pertussis booster vacci-
nation [2,3]. The aims of the present study were to
determine the distribution of IgG antibodies to
B. pertussis among different age groups in Turkey,
to evaluate the rate of decrease in vaccine-
acquired immunity, and to determine the optimal
age and frequency for booster immunisations.
Antibody levels to B. pertussis antigens were
measured in serum samples obtained from 550
(305 male, 245 female) healthy subjects, aged
4–24 years, who visited the Gazi University Med-
ical School well-child clinic, or the paediatric and
adolescent health examination clinics, for check-
up between April and June 2006, and who did not
have a prolonged history of coughing in the
preceding month. All study subjects had received
whole-cell pertussis vaccine three times in the
ﬁrst year of life, followed by a booster at the age
of 18 months. The whole-cell pertussis vaccines
used in Turkey for the last 20 years have been
obtained from several different foreign compa-
nies, and most recently from the Serum Institute
(Pune, India). Each single 0.5-mL dose contains
diphtheria toxoid £25 Lf, tetanus toxoid ‡5 Lf
and B. pertussis ‡4 IU, adsorbed on aluminium
phosphate ‡1.5 mg, with thiomersal 0.01% w ⁄v
as preservative (http://www.seruminsitute.com/
content/products/product_list.htm). Informed
Corresponding author and reprint requests: A. Duyan Camur-
dan, Devlet mahallesi, Sapka Devrimi Caddesi, Yesiloz sitesi
2 ⁄ 5, Eryaman 06374, Ankara, Turkey
E-mail: aysucamurdan@yahoo.com
388 Clinical Microbiology and Infection, Volume 14 Number 4, April 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 377–397
consent was obtained from all study participants,
and the Ethical Committee of the university
approved the study.
Serum samples were analysed using a commer-
cial ELISA kit (IBL-Hamburg GmbH, Hamburg,
Germany), with a manufacturer’s stated sensitiv-
ity of >95%. According to the manufacturer’s
classiﬁcation, values of <16 U ⁄mL, 16–24 U ⁄mL,
and >24 U ⁄mL were considered as negative,
equivocal and positive, respectively. Data were
analysed using SPSS v.10.0 (SPSS Inc., Chicago, IL,
USA), with p <0.05 considered to be signiﬁcant.
Antibody values for the different age groups were
analysed by Kruskal–Wallis variance analysis and
post-hoc Mann–Whitney U-tests. Comparisons of
antibody levels for each age group according to
gender were done using the Mann–Whitney
U-test. Antibody levels were given as geometric
mean titres (GMTs) according to age group.
Percentage distributions of antibody titres in the
ranges <16, 16–24, 25–50, 51–125, and >125 U ⁄mL
were also calculated for each age group.
The study population had a mean age of
12 ± 5.95 years (range 4–24 years). The popula-
tion was stratiﬁed into four groups according
to age: pre-school children (aged 4–6 years,
n = 87); elementary school children (aged 7–
12 years, n = 162); high school children (aged
13–18 years, n = 156); and young adults (aged 19–
24 years, n = 145).
GMTs of anti-pertussis antibody in subjects
aged 4–6 years were signiﬁcantly lower than in all
other age groups (p 0.0001). The GMT values
increased steadily in subjects who had started
elementary school, to 17.73 U ⁄mL in the group
aged 7–13 years, with the highest value of
51.14 U ⁄mL being in the group aged 13–18 years.
The values in the group aged 19–24 years were a
little lower (36.27 U ⁄mL), but the difference
among these three groups was not statistically
signiﬁcant (p >0.05) (Fig. 1).
Antibody levels ranged between 0.00001 U ⁄mL
and 313.58 U ⁄mL. The antibody values were not
associated with gender (p >0.05), and analysis of
age-stratiﬁed data according to gender also
revealed no signiﬁcant difference (p >0.05). The
frequency of anti-pertussis IgG titres for the
different age groups is shown in Fig. 2. Over half
(51.7%) of the children in the group aged
4–6 years were negative for pertussis antibodies,
and high-titre positivity was very low (8.1%) in
this age group. With increasing age, high-titre
positivity increased three-fold in the group aged
7–12 years, reaching 24.7%, and was at its peak
frequency (28.6%) in the group aged 13–17 years.
Information concerning age-speciﬁc antibody
levels against pertussis is required to target the
appropriate population for booster vaccination
[2]. A high degree of protection persists for
3 years after completion of infant immunisation,
but the vaccine antibodies begin to decrease
3–4 years after the last dose [2,4–6]. For this
reason, a booster dose is given in many countries
at the age of 3–6 years [3,7–9]. In Turkey, the ﬁnal
dose of pertussis vaccine is administered at the
age of 18 months, and the results of the present
study indicate that vaccine-induced immunity
decreases after 3–4 years.
350
300
250
200
150
100
50
14515616287
An
ti-
pe
rtu
ss
is 
Ig
G
 (P
T+
FH
A)
 (IU
/m
L)
0
–50
n =
Age groups (years)
4–6 7–12 13–18 19–24
Fig. 1. Occurrence of Bordetella pertussis (mixture of per-
tussis toxin (PT) and ﬁlamentous haemagglutinin (FHA))
IgG antibodies according to age group.
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Fig. 2. The frequency of anti-pertussis IgG titres (mixture
of pertussis toxin (PT) and ﬁlamentous haemagglutinin
(FHA)) in different age groups.
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The present study has several limitations. First,
the sample was based on the population attend-
ing a large university hospital and therefore does
not represent the entire community. However, the
serological trends observed were consistent in
many respects with international serosurveys
performed with healthy individuals. Second, the
ELISA used in this study does not discriminate
between responses for pertussis toxin and for
ﬁlamentous haemagglutinin; positive results
could also be obtained if cross-reactive antibodies
to ﬁlamentous haemagglutinin produced by other
bacteria were present in the sera. Nevertheless,
this study revealed that the GMT of pertussis
antibodies increased after the age of 6 years, with
the fastest increase being in the group aged
7–12 years. As there is no booster against pertus-
sis at this age, this increase reﬂects the acquisition
of natural immunity following the beginning of
elementary school at the age of 7 years, when
children join a new crowded community with a
high probability of communicable disease. These
children can then become a source of infection for
neonates and young infants who have not yet
completed their vaccination schedules [10].
In Turkey, diphtheria toxoid is administered
in the ﬁrst and eighth classes of elementary
school, when children are aged 7 and 15 years,
respectively. As the easiest way to reach older
children and adolescents is in schools, addition
of pertussis to the school vaccination schedule
may be the best means of administering booster
vaccination if this is logistically feasible. How-
ever, before ﬁnalising decisions concerning late
childhood and adolescent immunisation against
pertussis, evaluation of the health beneﬁts, risks,
costs and cost-effectiveness of pertussis vaccina-
tion in older children and adolescents in Turkey
is necessary.
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